Valuation: Scancell Holdings plc

Market Cap 11Cr 15Cr 13Cr 12Cr 21Cr 1.42TCr 21Cr 149.36Cr 59Cr 748.99Cr 57Cr 55Cr 2.39TCr P/E 2026
-8.09x
P/E 2027 * -3.75x
Enterprise Value 12Cr 16Cr 15Cr 14Cr 23Cr 1.56TCr 23Cr 163.16Cr 64Cr 818.2Cr 62Cr 61Cr 2.61TCr EV / Sales 2026
-
EV / Sales 2027 * 59.9x
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -
1 day-3.01%
1 week-3.53%
Current month-4.04%
1 month-7.96%
3 months-33.19%
6 months-31.92%
Current year-8.89%
1 week 89.5
Extreme 89.5
95
1 month 89.5
Extreme 89.5
99
Current year 89.5
Extreme 89.5
295
1 year 89.5
Extreme 89.5
295
3 years 72.6
Extreme 72.6
295
5 years 72.6
Extreme 72.6
295
10 years 1.12
Extreme 1.118
295
Manager TitleAgeSince
Chief Executive Officer 69 28/07/2021
Chief Executive Officer 64 18/11/2024
Director of Finance/CFO 50 24/04/2026
Director TitleAgeSince
Director/Board Member 69 17/11/2010
Director/Board Member 74 23/10/2019
Director/Board Member 64 24/09/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/09/25
Vulpes Investment Management Pte Ltd.
BuyCompany 31,50,000 0.3038%
08/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 1,02,236 0.0099%
04/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 44,00,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
-3.01%-3.53%-5.55%-34.40% 15Cr
-0.21%-6.36%+49.00%+74.13% 6.63TCr
-0.22%+6.53%+11.68%+90.35% 5.29TCr
+0.82%+9.46%+7.75%+73.53% 5.48TCr
+3.32%+5.69%+26.64%+50.74% 4.41TCr
+1.88%+9.78%+22.21%+128.69% 4.37TCr
-1.24%+0.67%+264.20%+961.35% 4.21TCr
+0.10%+9.96%+17.15%+59.33% 3.4TCr
-1.30%-3.61%+37.37%+7.16% 2.62TCr
+0.69%+5.60%+36.60%+26.39% 2.34TCr
Average +0.10%+4.25%+46.71%+143.73% 3.88TCr
Weighted average by Cap. +0.47%+4.67%+51.55%+167.43%

Financials

2026 2027 *
Net sales 12.5L 16.74L 14.92L 13.81L 23.55L 16Cr 23.83L 1.66Cr 64.98L 8.3Cr 62.81L 61.5L 26Cr 23.08L 30.91L 27.55L 25.5L 43.48L 29Cr 44L 3.06Cr 1.2Cr 15Cr 1.16Cr 1.14Cr 49Cr
Net income -1.92Cr -2.58Cr -2.3Cr -2.13Cr -3.62Cr -243.1Cr -3.67Cr -25Cr -10Cr -127.78Cr -9.66Cr -9.46Cr -407.19Cr -2.79Cr -3.74Cr -3.33Cr -3.09Cr -5.26Cr -353.16Cr -5.33Cr -37Cr -15Cr -185.63Cr -14Cr -14Cr -591.52Cr
Net Debt 1.04Cr 1.4Cr 1.24Cr 1.15Cr 1.96Cr 131.66Cr 1.99Cr 14Cr 5.42Cr 69Cr 5.23Cr 5.12Cr 220.52Cr 2.56Cr 3.42Cr 3.05Cr 2.83Cr 4.82Cr 323.2Cr 4.87Cr 34Cr 13Cr 169.89Cr 13Cr 13Cr 541.35Cr
Projected Income Statement - Annual - Scancell Holdings plc
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
55
Date Price Change Volume
21/26/21 GBX 90.20 -3.01% 87,877
20/26/20 GBX 93.00 0.00% 1,50,872
19/26/19 GBX 93.00 0.00% 82,543
16/26/16 GBX 93.00 -0.53% 27,870
15/26/15 GBX 93.50 0.00% 61,639
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9020GBP
Average target price
1.900GBP
Spread / Average Target
+110.64%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Scancell Holdings plc
  1. Stock Market
  2. Stocks
  3. SCLP Stock